Seletracetam (lithium)

• UNSPSC Description:

  Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy[1][2][3].

• Target Antigen:

  HIV

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Anti-infection

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/seletracetam-lithium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H](N1C(C[C@H](C1)/C=C(F)\F)=O)CC)N.[Li]

• Molecular Weight:

  239.17

• References & Citations:

  [1]Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7.|[2]Yang X, et al. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22.|[3]Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3